Our technologies help surgeons to detect cancer accurately in real time, advancing surgical precision, improving patient outcomes, and reducing costs for healthcare systems.
We have a strong pipeline of highly innovative technologies and an exceptional team working alongside leading international cancer centers and surgeons.
We are using next-generation miniaturized sensors to enable the engineering of miniaturized probes suitable in scale for the small laparoscopic ports used in state-of-the-art robotic surgery
Combined with new cancer-targeted imaging agents, such as PSMA, our probes can define entirely novel radio-guided surgical applications, promising a paradigm shift in the surgical treatment of cancer
By using the same cancer-target imaging agents, data from pre-operative scans along with intra-operative data from Lightpoint’s probes can be combined with AI to offer never-seen-before visualization of the surgical location and extent of any cancer
All aiding surgeons to find and remove cancer, transforming outcomes for patients and saving costs for healthcare systems
Our Founder and Executive Chair, Dr David Tuch, introduces Lightpoint and our new miniature surgical probe for intra-operative cancer detection, SENSEI®.
+18 million new cases of cancer will be diagnosed globally and the disease will account for one in six deaths
The incidence of cancer is forecast to rise by over 60% by 2030 with over 24 million new cases each year worldwide
Robots have transformed surgery in recent decades with minimally-invasive, robot-assisted cancer surgery now dominating clinical practice
However, despite the robotic advances, cancer is often left behind or, conversely, healthy tissue is needlessly removed, increasing the need for further drug treatment, radiotherapy, & surgery
Telix to expand late-stage urologic pipeline with acquisition of Lightpoint Medical and its radioguided surgery business
Congratulations to Professor Ronald Zweemer & Dr Kees Gerestein for publication of their clinical study results using SENSEI® in robot-assisted sentinel lymph node detection.
Congratulations to the team at UCLA Health in California for first use of SENSEI® in robot-assisted prostate cancer surgery in the US.
Professor Manish Chand launches clinical feasibility study using SENSEI® in robot-assisted colorectal cancer surgery at University College Hospital, London.